Novel Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation

References

• . Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983–988
   PubMed Web of Science ®Google Scholar
• . Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology. 2007;69(6):546–554
   PubMed Web of Science ®Google Scholar
• . Wang TJ, Massaro JM, Levy D, . A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA. 2003;290(8):1049–1056
   PubMed Web of Science ®Google Scholar
• . Hart RG, Halperin JL. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. Ann Intern Med. 1999;131(9):688–695
   Google Scholar
• . Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–867
   PubMed Web of Science ®Google Scholar
• . Ogilvie IM, Newton N, Weiner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123(7):638–645
   PubMed Web of Science ®Google Scholar
• . Ansell J, Hollowell J, Pengo V, Martinez-Brotons F, Caro J, Drouet L. Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM). J Thromb Thrombolysis. 2007;23(2):83–91
   PubMedGoogle Scholar
• . Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864–2870
   PubMed Web of Science ®Google Scholar
• . Go AS, Hylek EM, Chang Y, . Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA. 2003;290(20):2685–2692
   PubMed Web of Science ®Google Scholar
• . Olesen JB, Lip GY, Hansen ML, . Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124
   PubMed Web of Science ®Google Scholar
• . Camm AJ, Kirchhof P, Lip GY, ; European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369–2429
   PubMed Web of Science ®Google Scholar
• . Camm AJ, Lip GY, De Caterina R, ; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719–2747
   PubMed Web of Science ®Google Scholar
• . Fuster V, Ryden LE, Cannom DS, ; American College of Cardiology/Foundation/American Heart Association Task Force. 2011ACCF/ AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011;123(10):e269–e367
   PubMedGoogle Scholar
• . You JJ, Singer DE, Howard PA, ; American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141( 2 suppl):e531S–e575S
   PubMed Web of Science ®Google Scholar
• . Diener HC; Executive Steering Committee of the SPORTIF III and V Investigators. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies. Cerebrovasc Dis. 2006;21(4):279–293
   Google Scholar
• . Connolly SJ, Ezekowitz MD, Yusuf S, ; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151
   PubMed Web of Science ®Google Scholar
• . Connolly SJ, Ezekowitz MD, Yusuf S, ; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation [letter]. N Engl J Med. 2009;361(27):2675
   Google Scholar
• . Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L; Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial. N Engl J Med. 2010;363(19):1875–1876
   PubMed Web of Science ®Google Scholar
• . US Food and Drug Administration.FDA approves Pradaxa to prevent stroke in people with atrial fibrillation [news release]. Silver Springs, MD: US Food and Drug Administration; 2010. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm230241.htm. Accessed January 9, 2013
   Google Scholar
• . First novel blood thinner in 50 years for the prevention of strokes caused by common heart rhythm disorder, approved in EU. Manufacturing, net; 2011. http://www.manufacturing.net/news/2011/08/first-novel-blood-thinner-in-50-years-for-the-prevention-of-strokes-caused-by-common-heart-rhythm-disorder-approved-in-europe. Accessed January 9, 2013
   Google Scholar
• . Pradaxa [package insert]. Ingelheim am Rhein, Germany: Boehringer Ingelheim GmbH; 2012. http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829AVC500041059.pdf. Accessed January 9, 2013
   Google Scholar
• . Pradaxa [package insert]. Ridgefield, CT: Boehringer Ingelheim; 2012. http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf. Accessed January 9, 2013
   Google Scholar
• . Hariharan S, Madabushi R. Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment. J Clin Pharmacol. 2012;52( 1 suppl):119S–125S
   PubMed Web of Science ®Google Scholar
• . US Food and Drug Administration.FDA approves Xarelto to prevent stroke in people with common type of abnormal heart rhythm [news release]. Silver Springs, MD: US Food and Drug Administration; 2011. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm278646.htm. Accessed January 9, 2013
   Google Scholar
• . Xarelto [package insert]. Pittsburg, PA: Bayer Corporation; 2012. http://www.xareltohcp.com/sites/default/files/pdf/xarelto_0.pdf. Accessed January 9, 2013
   Google Scholar
• . Bayer's Xarelto® approved in the EU for the prevention of stroke in patients with AF and in the treatment of DVT [press release]. Berlin, Germany: Bayer Pharma AG; 2011. http://www.xarelto.com/html/press/pdf/2011-0648E.pdf. Accessed January 9, 2013
   Google Scholar
• . Bayer's Xarelto® (rivaroxaban) approved for the treatment of pulmonary embolism (PE) and the prevention of recurrent deep vein thrombosis (DVT) and PE in the EU [press release]. Berlin, Germany: Bayer Pharma AG; 2012. http://www.press.bayer.com/baynews/baynews.nsf/id/A14A35F3DFC809EDC1257ABB0053DD62/$File/2012-0533E. pdf. Accessed January 9, 2013
   Google Scholar
• . Xarelto [package insert]. Berlin, Germany: Bayer Pharma AG; 2012. http://www.xarelto.com/html/downloads/Xarelto-Prescribing_Information-Nov-2012.pdf. Accessed January 9, 2013
   Google Scholar
• . Patel MR, Mahaffey KW, Garg J, ; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891
   PubMed Web of Science ®Google Scholar
• . US Food and Drug Administration. FDA approves Eliquis to reduce the risk of stroke, blood clots in patients with non-valvular atrial fibrillation [press release]. Silver Springs, MD: US Food and Drug Administration; 2012. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333634.htm. Accessed January 9, 2013
   Google Scholar
• . Granger CB, Alexander JH, McMurray JJ, ; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992
   PubMed Web of Science ®Google Scholar
• . Connolly SJ, Eikelboom J, Joyner C, ; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806–817
   PubMed Web of Science ®Google Scholar
• . Eliquis [package insert]. Uxbridge, UK: Bristol-Myers Squibb/Pfizer EEIG; 2012. http://www.medicines.org.uk/emc/medicine/24988#INDICATIONS. Accessed January 9, 2013
   Google Scholar
• . ELIQUIS® (apixaban) approved in Europe for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation [press release]. Princeton, NJ: Bristol-Myers Squibb; 2012. http://news.bms.com/press-release/financial-news/eliquisapixaban-approved-europe-prevention-stroke-and-systemic-embolism&t=634890181706594412. Accessed January 9, 2013
   Google Scholar
• . Eliquis [package insert]. Princeton, NJ: Bristol-Myers Squibb; New York, NY: Pfizer Inc; 2012. http://packageinserts.bms.com/pi/pi_eliquis.pdf. Accessed January 9, 2013
   Google Scholar
• . Nessel C, Mahaffey K, Piccini J, . Incidence and outcomes of gastrointestinal hemorrhage in patients with atrial fibrillation treated with rivaroxaban or warfarin: results from the ROCKET AF trial [abstract]. Chest. 2012;142(4):84A
   Google Scholar
• . Hohnloser SH, Oldgren J, Yang S, . Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation. 2012;125(5):669–676
   PubMed Web of Science ®Google Scholar
• . Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med. 2012;172(5):397–402
   PubMed Web of Science ®Google Scholar
• . Mega JL, Braunwald E, Wiviott SD, ; ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9–19
   PubMed Web of Science ®Google Scholar
• . FDA issues complete response letter for XARELTO® (rivaroxaban) for the reduction of secondary cardiovascular events in patients with acute coronary syndrome [press release]. Raritan, NJ: Janssen Research & Development LLC; 2012. http://www.prnewswire.com/news-releases/fda-issues-complete-response-letter-for-xarelto-rivaroxaban-for-the-reduction-of-secondary-cardiovascular-events-in-patients-with-acute-coronary-syndrome-159935025.html. Accessed January 9, 2013
   Google Scholar
• . Complete response submitted to US FDA on Bayer's rivaroxaban for the reduction of secondary cardiovascular events in patients with acute coronary syndrome [press release]. Berlin, Germany: FiercePharma; September 7, 2012. http://www.fiercepharma.com/press-releases/complete-response-submitted-us-fda-bayers-rivaroxaban-reduction-secondary-c. Accessed January 9, 2013
   Google Scholar
• . Flaherty ML, Kissela B, Woo D, . The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology. 2007;68(2):116–121
   PubMed Web of Science ®Google Scholar
• . Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008;36(2):386–399
   PubMed Web of Science ®Google Scholar
• . Perzborn E, Roehrig S, Straub A, Kubitza D, Mueck W, Laux V. Rivaroxaban: a new oral factor Xa inhibitor. Arterioscler Thromb Vasc Biol. 2010;30(3):376–381
   PubMed Web of Science ®Google Scholar
• . Perzborn E, Roehrig S, Straub A, Kubitza D, Mizzelwitz F. The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat Rev Drug Discov. 2011;10(1):61–75
   PubMed Web of Science ®Google Scholar
• . Weinz C, Schwarz T, Kubitza D, Mueck W, Lang D. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs and humans. Drug Metab Dispos. 2009;37(5):1056–1064
   PubMed Web of Science ®Google Scholar
• . Carreiro J, Ansell J. Apixaban, an oral direct factor Xa inhibitor: awaiting the verdict. Expert Opin Investig Drugs. 2008;17(12):1937–1945
   PubMed Web of Science ®Google Scholar
• . Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124(14):1573–1579
   PubMed Web of Science ®Google Scholar
• . US Food and Drug Administration. FDA Drug Safety Communication: Update on the risk for serious bleeding events with the anticoagulant Pradaxa (dabigatran). 2012. http://www.fda.gov/Drugs/DrugSafety/ucm326580.htm. Accessed January 9, 2013
   Google Scholar
• . Connolly SJ, Wallentin L, Ezekowitz MD, . Randomized comparison of the effects of two doses of dabigatran etexilate on clinical outcomes over 4.3 years: results of the RELY-ABLE double-blind randomized trial. CS.04. Clinical Science: Special Reports: Valvular Heart Disease, PAD, Atrial Fibrillation: International Perspectives. Presented at: American Heart Association 2012 Scientific Sessions; November 7, 2012
   Google Scholar
• . Xarelto (rivaroxaban) [product monograph]. Toronto, Ontario, Canada: Bayer Inc; 2012. http://www.bayer.ca/files/XARELTO-PM-ENG-18JUL2012-154961.pdf. Accessed January 9, 2013
   Google Scholar
• . Pradax (dabigatran etexilate) [product monograph]. Burlington, Ontario, Canada: Boehringer Ingelheim Canada Ltd; 2012. http://www.boehringer-ingelheim.ca/content/dam/internet/opu/ca_EN/documents/humanhealth/productmonograph/Pradax-pm.pdf Accessed January 9, 2013
   Google Scholar
• . Patel MR, Hellkamp AS, Lokhnygina Y, . Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial [abstract]. Circulation. 2012;125:2445–2447
   Google Scholar
• . Granger CB, Alexander J, Hanna M, ; ARISTOTLE Investigators and Committees. Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial. Eur Heart J. 2012;33( suppl):685–686. Abstract 4045
   Google Scholar
• . Rose AJ, Hylek EM, Ozonoff A, Ash AS, Reisman JI, Berlowitz DR. Risk-adjusted percent time in therapeutic range as a quality indicator for outpatient oral anticoagulation: results of the Veterans Affairs Study to Improve Anticoagulation (VARIA). Circ Cardiovasc Qual Outcomes. 2011;4(1):22–29
   PubMed Web of Science ®Google Scholar
• . Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236–239
   PubMed Web of Science ®Google Scholar
• . Self TH, Reaves AB, Oliphant CS, Sands C. Does heart failure exacerbation increase response to warfarin? A critical review of the literature. Curr Med Res Opin. 2006;22(11):2089–2094
   PubMed Web of Science ®Google Scholar
• . Wallentin L, Yusuf S, Ezekowitz MD, ; RE-LY Investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376(9745):975–983
   PubMed Web of Science ®Google Scholar
• . Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–1100
   PubMed Web of Science ®Google Scholar
• . Hankey GJ, Patel MR, Stevens SR, ; ROCKET AF Steering Committee Investigators. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurology. 2012;11(4):315–322
   PubMed Web of Science ®Google Scholar
• . Diener HC, Connolly SJ, Ezekowitz MD, ; RE-LY Study Group. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol. 2010;9(12):1157–1163
   PubMed Web of Science ®Google Scholar
• . Easton JD, Lopes RD, Bahit MC, ; ARISTOTLE Committee and Investigators. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol. 2012;11(6):503–511
   PubMed Web of Science ®Google Scholar
• . Fang MC, Go AS, Chang Y, . A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011;58(4):395–401
   PubMed Web of Science ®Google Scholar
• . Go AS, Fang MC, Udaltsova N, ; ATRIA Study Investigators. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation. 2009;119(10):1363–1369
   PubMed Web of Science ®Google Scholar
• . Piccini JP, Stevens SR, Chang Y, et al; for the ROCKET AF Steering Committee and Investigators. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 Index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation. 2013;127(2):224–232
   Google Scholar
• . Fox KA, Piccini JP, Wojdyla D, . Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32(19):2387–2394
   PubMed Web of Science ®Google Scholar
• . Eikelboom JW, Wallentin L, Connolly SJ, . Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123(21):2363–2372
   PubMed Web of Science ®Google Scholar
• . Hohnloser SH, Hijazi Z, Thomas L, . Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012;33(22):2821–2830
   PubMed Web of Science ®Google Scholar
• . Agnelli G, Gallus A, Goldhaber SZ, ; ODIXa-DVT Study Investigators. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation. 2007;116(2):180–187
   PubMed Web of Science ®Google Scholar
• . Büller HR, Lensing AW, Prins MH, ; Einstein-DVT Dose-Ranging Study Investigators. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis. The EINSTEIN-DVT Dose-Ranging Study. Blood. 2008;112(6):2242–2247
   PubMed Web of Science ®Google Scholar
• . Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296–1310
   PubMed Web of Science ®Google Scholar
• . Llor C, Sierra N, Hernandez S, . The higher the number of daily doses of antibiotic treatment in lower respiratory tract infection the worse the compliance. J Antimicrob Chemother. 2009;63(2):396–399
   Google Scholar
• . Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care. 2009;15(6):e22–e33
   PubMed Web of Science ®Google Scholar